CM
CRNX icon

Caption Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Caption Management’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-75,100
Closed -$3.5M – 1644
2025
Q4 		$3.5M Sell
75,100
-113,100
-60% -$5.04M 0.02% 627
2025
Q3 		$7.84M Buy
188,200
+168,200
+841% +$5.38M 0.06% 350
2025
Q2 		$575K Buy
+20,000
New +$618K 0.01% 1076
2024
Q3 		– Sell
-199,000
Closed -$8.91M – 1342
2024
Q2 		$8.91M Sell
199,000
-120,000
-38% -$5.54M 0.14% 157
2024
Q1 		$14.9M Buy
319,000
+243,800
+324% +$9.54M 0.23% 108
2023
Q4 		$2.68M Sell
75,200
-124,800
-62% -$3.83M 0.04% 528
2023
Q3 		$5.95M Buy
+200,000
New +$4.12M 0.09% 275

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Caption Management's CRNX Position: Q2 2025 in Review

Caption Management sold out of Crinetics Pharmaceuticals (CRNX) in Q2 2025, closing a stake of 86,713 shares — an estimated $2.68M sold.

Caption Management first reported a position in CRNX in Q4 2023 and held it in 2 quarters. The position peaked at $2.91M in Q1 2025. 222 funds tracked by Wall St. Rank hold CRNX as of Q2 2025.

  • Caption Management reported no remaining Crinetics Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Caption Management sold 86,713 Crinetics Pharmaceuticals shares in Q2 2025, an estimated $2.68M.
  • Caption Management first reported a position in Crinetics Pharmaceuticals in Q4 2023 and held it in 2 quarters.
  • Caption Management's Crinetics Pharmaceuticals position peaked at $2.91M in Q1 2025.
  • 222 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2025.

Based on Caption Management's 13F filing for Q2 2025, filed 14 Aug 2025.